Subject: Specialty Quantity Limit pomalidomide-Pomalyst 2387-H P2025

Drug

POMALYST  (pomalidomide)

Policy:

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Pomalyst (pomalidomide) capsules 1 mg	21 per 28 days
Pomalyst (pomalidomide) capsules 2 mg	21 per 28 days
Pomalyst (pomalidomide) capsules 3 mg	21 per 28 days
Pomalyst (pomalidomide) capsules 4 mg	21 per 28 days

FDA-Recommended Dosing

Multiple Myeloma

4 mg once daily taken orally on days 1-21 of repeated 28-day cycles

Kaposi Sarcoma

5 mg once daily taken orally on days 1-21 of repeated 28-day cycles

Dosage Modifications

1 mg to 4 mg once daily

Dose reductions are recommended for adverse reactions, drug interactions, severe renal impairment with hemodialysis and hepatic impairment.

Place of Service:

Outpatient

The above policy is based on the following references:

1. Pomalyst [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; February 2025.
2. Pomalidomide [package insert]. Piscataway, NJ: Camber Pharmaceuticals, Inc.; November 2025.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 18, 2026